List of Immuno-Assays Companies in China - 12

Kewei's products include the diagnostic kits of hepatitis B surface antigen, hepatitis B surface antibody, hepatitis B 'e' antigen, hepatitis B 'e' antibody and hepatitis B core antibody, hepatitis a virus IgM diagnostic kits, hepatitis E virus IgM diagnostic kits, RPR diagnostic kits, HBV test cassettes, HIV Ag/Ab diagnostic kits, etc.

Established in 2012, BravoVax is located at BravoVax Building, 858 Gaoxin Avenue in the state-level biopharma development zone, Donghu hi-tech park of Wuhan, China. Relying on the experienced management team and international channels from parent company BravoBio and strong support from Humanwell Healthcare Group, one of the top 20 Chinese pharmaceuticals, we have kept the momentum in its development, maintaining fast growth. We are committed to the research and development of human vaccines and other biological products. The new pilot facility and R&D center are built at Wuhan biopharaceutical industrial park as per cGMP. All staffs hold a college and above degree, and more than 30% of them have master and above degrees as well as senior professional titles.

Eachy Biopharmaceuticals, Ltd is a ISO 13485 qualified company focused on developing and producing in vitro diagnostics for the prognosis of cardiovascular diseases, metabolic syndrome and the diagnosis of inflammatory diseases.AccuRapid SARS-CoV-2 IgM/IgG Test Kit (Lateral Flow Immunoassay) - EU CE Mark 32020

Fapon is a global leading life sciences company dedicated to providing integrated solutions and services for diagnostics, biopharma and biotherapy. Integrating a one-stop solution on raw materials, reagents and innovative open instrument platforms, the Company has grown into a leading supplier in in-vitro diagnostics. Fapon boasts advanced innovations in therapeutics technologies and AI algorithm platforms with data insights that contribute to a better and healthier world. Supported by its strong global R&D, manufacturing, sales and service network, Fapon's products have established presence in 68 countries and regions, serving more than 2,500 business partners worldwide.

Founded in 1992 and listed in 2015, Wondfo is a fast-growing biotechnology company in China. Wondfo mainly focuses on rapid diagnostics in China but is looking for further development in other areas of the healthcare industry. Besides the headquarter in Guangzhou, Wondfo also owns 2 overseas labs, 1 branch in Chicago, and 11 overseas offices. After many years’ efforts in delivering high-quality products and services, Wondfo has won a good reputation around the world. In production, Wondfo strictly complies with national and international regulations and standards. We have got CE certificates, FDA certificates, FSC certificates, ISO 9001:2008, and ISO 13485:2012 quality system certification. Wondfo attaches great importance to research and development and sees innovation as the soul of the enterprise’s development. So far, Wondfo has 530+ highly-qualified researchers and over 30% of the staff have obtained master's and doctorate degrees from prestigious universities worldwide. Wondfo also has built R&D laboratories in Guangzhou and San Diego. With our advanced production lines and highly experienced staff, Wondfo’s daily production capacity of test kits reaches 1.5 million. Wondfo also provides a number of customized services to professional distributors and partnering affiliates. Wondfo provides high-quality products at a very competitive price, together with professional technical support and counseling service. Currently, Wondfo has customers in more than 120 countries and areas. It is our commitment to safeguarding the health and improving lives with better products, services, and solutions. With more than 3000 dedicated employees, we'll continue to innovate and shape the future of POCT and healthcare.

Founded in 2015 with the pursuit for human and global health,Testsealabs Inc.creates innovative tech-nologies for the development of raw materials for diagnostic use.We offer diagnostic total solution such as rapid diaqnostic tests(RDTs),fluorescent immuno-diaqnostic tests, ELISA,molecular diagnostic tests(MDx)and clinical chemistry. We specialize in developing monoclonal antibodies and recombinant antigens in-house at our facility in China.We also have patented technoloqies includingfluorescentimmuno-diagnostics which will be one of the major IVD technologies of the future. Our facility is GMP,ISO9001and ISO13458 certified and we have CE FDA approval. Now we are looking forward to cooperating with more overseas companies for mutual development. Since its establishment,Testsealabs Inc has always insisted on R&D and innovation. At present, it has accumulated 1 software copyright and 50 authorized patents, including 4 invention patents, 46 new patents for use, and several special projects under application. Testsealabs Inc currently has more than 300 employees, an annual output of 300 million people, and a business area of 56,000 square meters. We pursuing the concept of "integrity, quality and responsibility", adhering to the tenet of quality first and serving the society, we constantly strive to develop new high-quality diagnostic raw materials, always adhere to the vision of serving the society and a healthy world, and are committed to promoting high-quality diagnostic products. Accurate diagnosis of all human diseases contributes to the cause of human health. Always find us here for solutions!

Gene fragment analysis applications

ImmuneOnco Biopharmaceuticals (Shanghai) Co.,Ltd., founded in June 2015 in Zhangjiang High-Tech Park of Shanghai, China, is an clinical-stage biopharmaceutical company dedicated to development and commercialization of novel cancer immunotherapeutics that reverse cancer cell-induced immune inhibition and actively eradicate cancer cells. To achieve these goals, we have established several proprietary platforms harnessing two types of innate immune cells, macrophages and natural killer (NK) cells, to fulfill the cancer-killing tasks. Macrophages play critical roles in fighting cancer through phagocytosis followed by tumor antigen presentation to T cells, which in turn destroy antigen-expressing tumor cells. However, cancer cells have evolved to evade immune surveillance, by mechanisms such as over-expressing CD47 and inhibiting phagocytosis via interaction with signal regulatory protein (SIRPα) on macrophages. We are developing a pipeline of compounds for reversing cancer cell-induced inhibition of innate immunity. NK cells are innate defense mechanisms of the body against viral infection and cancer, which directly target pathogenic cells without requirement for MHC recognition. We have established proprietary platforms and target-activated NK (TANK™) cell therapy for treatment of both leukemia and solid tumors. ImmuneOnco is actively advancing pipelines of proprietary platform-based compounds targeting a broad range of canncer indications.

Nantong Diagnos Biotechnology Co., Ltd. (Diagnos) is a professional POCT(point-of-care testing) manufacturer in China, found in 2006, specialized in researching, developing, manufacturing and distributing advanced medical instruments and in-vitro medical diagnostic products. Diagnos offers quality products in the following specialties: Fertility, Infectious Diseases, Tumor Markers, Cardiac Markers, Substance of Drug Abuse tests and etc.(2019-nCoV) New coronavirus Antibody Test (Colloidal Gold)

Sansure Biotech Inc., now a listed company in China, established in 2008, is an integrated solutions manufacturer and provider with independent innovation of molecular diagnostics and gene technology, has over 10-year experience specialized in diagnostic reagents, nucleic acid diagnostic instruments, complete lab solutions and lab chain services. Sansure solutions for molecular diagnosis are compatible with majority of PCR detection instruments and lab environments based on unique technical platforms “global leading magnetic beads extraction system”, “one of the simplest and fastest one-step DNA/RNA lysis systems”, automated nucleic acid extraction system, POCT devices and real-time PCR instruments. Over 40% of its employees work for R&D and technical service departments, over one hundred of products with global registrations, including infectious diseases, cancer, maternal and child health, blood screening, emerging infectious diseases prevention and control, chronic disease management, etc. "Sansure solutions" have been widely used in nearly 160 countries worldwide, such as France, UK, Germany, Russia, the Philippines, Brazil etc., obtained certificates in over 65 countries, include NMPA China, US FDA EUA，ANVISA, TGA Australia, We are one of the companies with the largest number of overseas certificates. For more information, please contact us at info@sansure.com.cn

Established in 1981, Shanghai Kehua Bio-engineering Co., Ltd (KHB) is one of the largest developers, manufacturers and marketers of in vitro diagnostic products in China. In July 2004, we became the first listed company in Shen Zhen Stock Exchange focused on the IVD business. We offer a broad range of products covering three primary business segments: Diagnostic Reagents, Diagnostic Laboratory Instruments, and Evacuated Receptacles.

Snibe is a leading brand of Chemiluminescence immunoassay solution from Shenzhen, China. Also, Snibe is the first company who received FDA cleared on Chemiluminescence immunoassay product in China. With more than 2600 staffs, Snibe has been focusing on Chemiluminescence immunoassay solution for 29 years. At present, Snibe's products have been widely exported to more than 150 countries with 30000 installations globally. Best Quality, Best Service is our target. Snibe would like to be the pioneer in global diagnosis field.